These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28770623)

  • 1. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER 2 and angiogenesis in gastric cancer.
    Jomrich G; Schoppmann SF
    Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab: a novel antiangiogenic agent.
    Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
    Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment.
    Barzi A; Thara E
    Expert Opin Biol Ther; 2014 Sep; 14(9):1319-32. PubMed ID: 24881691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of ramucirumab for the treatment of colorectal cancer.
    Noguerido A; Mulet-Margalef N; Matos I; Ros J; Argilés G; Élez E; Tabernero J
    Expert Opin Drug Saf; 2018 Sep; 17(9):945-951. PubMed ID: 30073902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
    Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
    Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
    Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
    Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
    Narita Y; Muro K
    Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
    Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model.
    Wu JQ; Fan RY; Zhang SR; Li CY; Shen LZ; Wei P; He ZH; He MF
    Life Sci; 2020 Apr; 247():117402. PubMed ID: 32035930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo.
    Mashima T; Wakatsuki T; Kawata N; Jang MK; Nagamori A; Yoshida H; Nakamura K; Migita T; Seimiya H; Yamaguchi K
    Sci Rep; 2021 Jul; 11(1):15125. PubMed ID: 34302038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF as a potential target in lung cancer.
    Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
    Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target.
    Gambardella V; Castillo J; Tarazona N; Gimeno-Valiente F; Martínez-Ciarpaglini C; Cabeza-Segura M; Roselló S; Roda D; Huerta M; Cervantes A; Fleitas T
    Cancer Treat Rev; 2020 Jun; 86():102015. PubMed ID: 32248000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical review on ramucirumab in the treatment of advanced urothelial cancer.
    Vlachostergios PJ; Lee A; Thomas C; Walsh R; Tagawa ST
    Future Oncol; 2018 May; 14(11):1049-1061. PubMed ID: 29231057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Smyth EC; Tarazona N; Chau I
    Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.